CAR-T Cell Therapy for Progressive Multiple Sclerosis
Part of Brain & nervous system, Immune system & allergy clinical trials.
This trial tests a new cell therapy called S103 for people with MS that isn't responding well to standard treatments. The therapy involves modifying immune cells in the lab and putting them back into your body to help control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Diagnosed with Multiple Sclerosis using current diagnostic criteria
- MS that is getting worse or not responding to standard MS medicines
- Disability score (EDSS) between 2.0 and 7.0, meaning mild to moderate-to-severe disability
- Age 18–75 years old
- No active serious infections, HIV, hepatitis, or other autoimmune diseases besides MS
- Reasonable organ and blood cell function (liver, kidneys, heart, and blood counts)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a type of immunotherapy called CAR-T cells (made from your own immune cells) to see if it can help slow or stop progressive multiple sclerosis. It is a very early safety study, so only people with progressive MS who meet strict health criteria can join.
This trial tests a new treatment called MB-CART2019.1, which uses your own immune cells to fight multiple sclerosis. It is for people with progressive or worsening MS who have not responded well to other treatments.
This trial tests a new cell therapy called SYS6020 for people with multiple sclerosis that has not improved with standard treatments. The goal is to see if it can slow or stop the disease and improve symptoms.
This study tests a new cell therapy called CAR-T (using your own immune cells) for people with severe autoimmune diseases like lupus, scleroderma, or myositis that have not improved with standard treatments. The goal is to see if it can safely reduce disease activity.
This trial tests a universal CAR-T cell treatment for people with autoimmune diseases of the nervous system that haven't responded to standard therapies. It aims to see if this therapy can help control diseases like neuromyelitis optica, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and multiple sclerosis.
This early-phase trial tests CT103A “CAR-T” cell therapy to treat certain relapsing or treatment-resistant autoimmune diseases that affect the nervous system. It aims to see whether the cells are safe and may help reduce disease activity when standard treatments haven’t controlled symptoms.
Hear when a new Multiple Sclerosis (MS) Primary Progressive trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.